Omalkhair Abulkhair - Concepedia

Author

Omalkhair Abulkhair

Also Known As

Abulkhair, Omalkhair, O Abulkhair, O. A. M. Abulkhair, O. Abulkhair, O.A. Abulkhair, Omalkhair A Abulkhair, Omalkhair A. Abulkhair, Omalkhair A. M. Abulkhair, Omalkhair Abulkhair

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

King Abdulaziz Medical City King Saud bin Abdulaziz University for Health Sciences National Guard Health Affairs Istituti di Ricovero e Cura a Carattere Scientifico European Institute of Oncology

About

Omalkhair Abulkhair is an author at King Abdulaziz Medical City specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	989
2	Health Sciences	2	2	39
3	Public Health	2	2	47
4	Biochemistry	1	1	23
5	Cell Biology	1	1	23

Omalkhair Abulkhair

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4) Shani Paluch–Shimon, Fátima Cardoso, Ann H. Partridge, Annals of Oncology Breast OncologyInternational Consensus GuidelinesMedicineGynecologyEso–esmo 4Th	2020	248
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) Shani Paluch–Shimon, Olivia Pagani, Ann H. Partridge, The Breast Breast OncologyInternational Consensus GuidelinesMedicineCancer ManagementGynecology	2017	243
ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5) Shani Paluch–Shimon, Fátima Cardoso, Ann H. Partridge, Annals of Oncology Breast OncologyMedicineGynecologyBreast CancerYoung Women	2022	197
First international consensus guidelines for breast cancer in young women (BCY1) Ann H. Partridge, Olivia Pagani, Omalkhair Abulkhair, The Breast	2014	156
Use of Complementary and Alternative Medicine by Patients with Cancer in Saudi Arabia Abdul Rahman Jazieh, Reem Al Sudairy, Omalkhair Abulkhair, The Journal of Alternative and Complementary Medicine	2012	118
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) Thomas Bachelot, Eva Ciruelos, Fabio Puglisi, Annals of Oncology Metastatic Breast CancerBreast OncologyMedicinePathologyPreliminary Safety	2019	111
The first national public breast cancer screening program in Saudi Arabia Omalkhair Abulkhair, Fatina M. Al Tahan, Susan E. Young, Annals of Saudi Medicine	2010	87
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication David Miles, Eva Ciruelos, Fabio Puglisi, Annals of Oncology	2021	83
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients Joseph Gligorov, Beyhan Ataseven, Mark Verrill, European Journal of Cancer Breast OncologyMedicinePrimary AnalysisAdjuvant TreatmentBreast Cancer	2017	46
Modification and Implementation of NCCN Guidelines™ on Breast Cancer in the Middle East and North Africa Region Omalkhair Abulkhair, Nagi S. El Saghir, Lobna Sedky, Journal of the National Comprehensive Cancer Network	2010	45

Page 1